Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Accelerated Approval

<< Previous

Bullboard Posts

Next >>

Post by jmm1228on Jun 30, 2023 10:49am

331 Views

Post# 35522231

Accelerated Approval

I am no expert on the subject but it appears to me that AA can and has been granted before BTD. The AA guidelines favor cancer treatments, especially those with low adverse adverse reactions. Ruvidar should meet these standards.

<< Previous

Bullboard Posts

Next >>

Despite controversy, EA stock rises amid new ‘Dragon Age’ release